The global COPD drug delivery device market is anticipated to grow at a CAGR of around 4.5% during the forecast period 2020 to 2027 and to reach around US$ 12.0 Bn by 2027.
Increasing prevalence of chronic respiratory diseases across the globe, rapid advancements in medical devices, and players focus on development of smart/digital inhalers are factors expected to drive the growth of the global market. According to U.S. Department of Health and Human Services, currently more than 25 million people in the United States have asthma and approximately 14.8 million adults have been diagnosed with COPD. In addition, government of developed and developing countries is spending high on development of healthcare sector and increasing public private partnership for R&D activities are factors expected to support the growth of target market.
Major players are focused on enhancing the business presence in order to increase the customer base and increase profit which is expected to augment the growth of target market.
In 2018, Koninklijke Philips N.V. launched InnoSpire Go smallest and lightest portable hand-held nebulizer that provides portable, fast and effective medication delivery. This is expected to help the company to enhance the customer base.
In 2020, AireHealth acquired BreathResearch’s research and patents, which include work on machine learning analytics for respiratory condition tracking. This is expected to help the company to enhance the product portfolio.
In 2019, Hill-Rom, Inc., a company focused on making hospital beds, furniture, other health care equipment, and medical technology systems acquired Breathe Technologies, a global provider of a wearable ventilator for people with lung conditions such as chronic obstructive pulmonary disease. This is expected to help the company to enhance the customer base.
In 2019, Cipla Limited that primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions launched Niveoli for use in respiratory inhalation therapy. This is expected to help the company to enhance the customer base.
In 2020, Glenmark Pharmaceuticals a generic drug and active pharmaceutical ingredient manufacturer launched triple therapy inhaler in India market for patients suffering from chronic COPD. This is expected to help the company to strengthen its position in global market.
Rising number of geriatric population in developing countries and demand for minimal invasive drug delivery solution is expected to impact positively on the growth of target market.
However, factors such as stringent government regulation related to product approval and high cost associated to product and R&D activities are expected to hamper the growth of global COPD drug delivery device market. In addition, lack of reimbursement policies in developing countries is expected to challenge the growth of target market.
Technological advancements by major players and inclination towards tracking the untapped market in emerging economies are factors expected to create new opportunities for players operating in the target market over the forecast period. In addition, players focus on online channel in order to enhance the customer reach is expected to support the revenue growth of target market.
Segment Analysis by Region
The market in North America is expected to account for significant revenue share owing to increasing number of outpatients in hospitals suffering from COPD. In addition, presence of large number of players operating in the country, high investment for R&D activities, along with introduction of innovative solutions are factors expected to support the growth of regional market.
Major players focus on enhancing the business presence through partnerships and agreements is expected to further boost the growth of target market.
The global market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Global COPD Drug Delivery Device Market
2016 – 2027
2020 – 2027
Product, Type, Distribution Channel, End Use and Geography
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
COPD Drug Delivery Device Market Segment Analysis, 2019
The global market is segmented into product, type, distribution channel, and end use. The product segment is bifurcated into inhalers and nebulizers. The inhaler segment is expected to account for significant revenue share in the target market due to increasing product development activities by major players.
The distribution channel segment is further divided into online and offline; online channel is expected to witness faster growth in the global market due to flourishing e-commerce sector and players focus on increasing the customer base.
The players profiled in the report are Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries, Merck & Co., Inc., Cipla Inc., Sunovion Pharmaceuticals, Inc., Koninklijke Philips N.V., AstraZeneca, PARI GmbH, and Omron Corporation.
Market By Product
Market By Type
Market By Distribution Channel
Market By End Use
Market By Region
Middle East & Africa
The global COPD drug delivery device market in 2027 is expected to be above US$ 12.0 Bn.
The CAGR of the global COPD drug delivery device market from 2020-2027 is above 4.5%.
In end use segment the homecare setting segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
North America held the largest share in the global COPD drug delivery device market
In product segment the nebulizers segment is growing at faster pace
Some of the players considered in the report scope are Koninklijke Philips N.V., AstraZeneca, PARI GmbH, and Omron Corporation.